Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
Más filtros

Medicinas Complementárias
País/Región como asunto
Intervalo de año de publicación
1.
Sci Rep ; 7(1): 12348, 2017 09 27.
Artículo en Inglés | MEDLINE | ID: mdl-28955042

RESUMEN

The molecular mechanisms of maladaptive response in liver tissue with respect to the acute and post-acute phase of sepsis are not yet fully understood. Long-term sepsis survivors might develop hepatocellular/hepatobiliary injury and fibrosis. Here, we demonstrate that acid sphingomyelinase, an important regulator of hepatocyte apoptosis and hepatic stellate cell (HSC) activation, is linked to the promotion of liver dysfunction in the acute phase of sepsis as well as to fibrogenesis in the long-term. In both phases, we observed a beneficial effect of partial genetic sphingomyelinase deficiency in heterozygous animals (smpd1+/-) on oxidative stress levels, hepatobiliary function, macrophage infiltration and on HSC activation. Strikingly, similar to heterozygote expression of SMPD1, either preventative (p-smpd1+/+) or therapeutic (t-smpd1+/+) pharmacological treatment strategies with desipramine - a functional inhibitor of acid sphingomyelinase (FIASMA) - significantly improved liver function and survival. The inhibition of sphingomyelinase exhibited a protective effect on liver function in the acute-phase, and the reduction of HSC activation diminished development of sepsis-associated liver fibrosis in the post-acute phase of sepsis. In summary, targeting sphingomyelinase with FDA-approved drugs is a novel promising strategy to overcome sepsis-induced liver dysfunction.


Asunto(s)
Desipramina/farmacología , Cirrosis Hepática/prevención & control , Hígado/efectos de los fármacos , Sepsis/complicaciones , Esfingomielina Fosfodiesterasa/antagonistas & inhibidores , Animales , Apoptosis/efectos de los fármacos , Línea Celular , Desipramina/uso terapéutico , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Femenino , Células Estrelladas Hepáticas/efectos de los fármacos , Células Estrelladas Hepáticas/patología , Humanos , Hígado/citología , Hígado/patología , Cirrosis Hepática/etiología , Cirrosis Hepática/patología , Masculino , Ratones , Ratones Transgénicos , Estrés Oxidativo/efectos de los fármacos , Esfingomielina Fosfodiesterasa/genética , Esfingomielina Fosfodiesterasa/metabolismo , Resultado del Tratamiento
2.
s.l; s.n; 2017. tab.
No convencional en Español | BIGG | ID: biblio-964005

RESUMEN

Objetivos: El objetivo principal de esta Guía es recoger recomendaciones concretas basadas en los resultados de la literatura científica para tratar a pacientes con un trastorno mental grave y un consumo de sustancias atendidos en centros de tratamiento hospitalarios y ambulatorios. Incluye: 1) Recomendaciones farmacológicas y psicológicas para el tratamiento de los pacientes con un un trastorno depresivo mayor y un trastorno por uso de sustancias (cocaína, cannabis, alcohol, nicotina). 2) Recomendaciones farmacológicas y psicológicas para el tratamiento de los pacientes con trastorno del espectro esquizofrénico y un trastorno por uso de sustancias (cocaína, cannabis, alcohol, nicotina). 3) Recomendaciones farmacológicas y psicológicas para el tratamiento de los pacientes con un un trastorno de ansiedad y un trastorno por uso de sustancias (cocaína, cannabis, alcohol, nicotina). 4) Recomendaciones farmacológicas y psicológicas para el tratamiento de los pacientes con un un trastorno bipolar y un trastorno por uso de sustancias (cocaína, cannabis, alcohol, nicotina). 5) Recomendaciones farmacológicas y psicológicas para el tratamiento de los pacientes con un un trastorno por déficit de atención e hiperactividad y un trastorno por uso de sustancias (cocaína, cannabis, alcohol, nicotina).


Asunto(s)
Humanos , Adulto , Antipsicóticos/uso terapéutico , Trastornos Relacionados con Sustancias/tratamiento farmacológico , Trastornos Mentales/tratamiento farmacológico , Antidepresivos/uso terapéutico , Terapia Psicoanalítica , Buspirona/uso terapéutico , Bupropión/uso terapéutico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Clozapina/uso terapéutico , Agonistas de Dopamina/uso terapéutico , Desipramina/uso terapéutico , Disulfiram/uso terapéutico , Vareniclina/uso terapéutico , Naltrexona/uso terapéutico
3.
Psychopharmacology (Berl) ; 232(16): 2921-38, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25877744

RESUMEN

RATIONALE: Major depression has been associated with higher levels of air pollution that in turn leads to neurodegeneration via increased oxidative stress. There is a need for suitable translational animal models to study the role of oxidative stress in depression and antidepressant action. OBJECTIVE: Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat. In addition, response to the antioxidant melatonin, and the antidepressants desipramine or escitalopram, was assessed. METHODS: Rats were exposed to ozone (0.0 or 0.3 parts per million (ppm)) per inhalation for 4 h daily for a period of 15 days, while simultaneously receiving saline or the above-mentioned drugs. RESULTS: The data indicate that chronic ozone inhalation induced memory impairment, anxiety and depression-like effects, reduced cortical and hippocampal superoxide dismutase and catalase activity, and compromised central monoamine levels similar to that noted in depression. Moreover, the behavioral and neurochemical effects of melatonin, desipramine, and escitalopram were mostly attenuated in the presence of ozone. CONCLUSION: Thus, genetically susceptible individuals exposed to high levels of oxidative stress are at higher risk of developing mood and/or an anxiety disorders, showing greater redox imbalance and altered behavior. These animals are also more resistant to contemporary antidepressant treatment. The presented model provides robust face, construct, and predictive validity, suitable for studying neuronal oxidative stress in depression, antidepressant action and mechanisms to prevent neuronal oxidative stress.


Asunto(s)
Antidepresivos/uso terapéutico , Conducta Animal/efectos de los fármacos , Depresión/tratamiento farmacológico , Modelos Animales de Enfermedad , Estrés Oxidativo/efectos de los fármacos , Ozono/farmacología , Animales , Antidepresivos/farmacología , Citalopram/farmacología , Citalopram/uso terapéutico , Depresión/metabolismo , Trastorno Depresivo Mayor/tratamiento farmacológico , Trastorno Depresivo Mayor/metabolismo , Desipramina/farmacología , Desipramina/uso terapéutico , Hipocampo/efectos de los fármacos , Masculino , Melatonina/farmacología , Ratas
4.
Biol Psychiatry ; 70(11): 1039-48, 2011 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-21920503

RESUMEN

BACKGROUND: Perseveration and sensorimotor gating deficits are core features of obsessive-compulsive disorder (OCD). Serotonin 1B receptor (5-HT1BR) agonists exacerbate OCD symptoms in patients and induce perseveration and sensorimotor gating deficits in mice. Serotonin reuptake inhibitors (SRIs), but not noradrenaline reuptake inhibitors (NRIs), reduce OCD symptoms following 4 to 8 weeks of treatment. Using mice, we compared the effects of chronic SRI versus NRI treatment on 5-HT1BR-induced OCD-like behavior and 5-HT1BR sensitivity in orbitofrontal-subcortical OCD circuits. Furthermore, we localized the 5-HT1BR population that mediates OCD-like behavior. METHODS: Mice chronically received the SRI clomipramine or the NRI desipramine and were examined for 5-HT1BR-induced OCD-like behavior or 5-HT1BR binding and G-protein coupling in caudate putamen, nucleus accumbens, and orbitofrontal cortex. Separate mice were tested for OCD- or depression-like behavior following 4, 14, 21, 28, or 56 days of SRI treatment. Finally, OCD-like behavior was assessed following intra-orbitofrontal 5-HT1BR agonist infusion or intra-orbitofrontal 5-HT1BR antagonist infusion coupled with systemic 5-HT1BR agonist treatment. RESULTS: Effective, but not ineffective, OCD treatments reduced OCD-like behavior in mice with a time course that parallels the delayed therapeutic onset in OCD patients and downregulated 5-HT1BR expression in the orbitofrontal cortex. Intra-orbitofrontal 5-HT1BR agonist infusion induced OCD-like behavior, and intra-orbitofrontal 5-HT1BR antagonist infusion blocked OCD-like effects of systemic 5-HT1BR agonist treatment. CONCLUSIONS: These results indicate that orbitofrontal 5-HT1BRs are necessary and sufficient to induce OCD-like behavior in mice and that SRI pharmacotherapy reduces OCD-like behavior by desensitizing orbitofrontal 5-HT1BRs. Our findings suggest an essential role for orbitofrontal 5-HT1BRs in OCD pathophysiology and treatment.


Asunto(s)
Trastorno Obsesivo Compulsivo/patología , Corteza Prefrontal/metabolismo , Receptor de Serotonina 5-HT1B/metabolismo , 8-Hidroxi-2-(di-n-propilamino)tetralin/toxicidad , Estimulación Acústica/efectos adversos , Inhibidores de Captación Adrenérgica/farmacología , Inhibidores de Captación Adrenérgica/uso terapéutico , Antagonistas Adrenérgicos beta/farmacocinética , Animales , Clomipramina/farmacología , Clomipramina/uso terapéutico , Desipramina/farmacología , Desipramina/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Conducta Exploratoria/efectos de los fármacos , Femenino , Guanosina 5'-O-(3-Tiotrifosfato)/farmacocinética , Indoles/toxicidad , Yodocianopindolol/farmacocinética , Isótopos/farmacocinética , Ratones , Ratones Endogámicos BALB C , Inhibición Neural/efectos de los fármacos , Trastorno Obsesivo Compulsivo/inducido químicamente , Trastorno Obsesivo Compulsivo/tratamiento farmacológico , Agonistas de Receptores de Serotonina/toxicidad , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Natación/psicología , Factores de Tiempo
5.
Prog Neuropsychopharmacol Biol Psychiatry ; 32(2): 348-55, 2008 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-17888556

RESUMEN

Stereotypy is an important manifestation of obsessive compulsive disorder (OCD). OCD involves disturbed serotonin and dopamine pathways, and demonstrates a selective response to serotonin reuptake inhibitors (SRI), with limited to no response to noradrenaline reuptake inhibitors (NRI). Deer mice (Peromyscus maniculatus bairdii) engage in various spontaneous stereotypic behaviours, including somersaulting, jumping and pattern running, and has to date not been explored for possible relevance for OCD. We studied the population diversity of spontaneous stereotypy in these animals, followed by assessing behavioural response to chronic high and low dose SRI (viz. fluoxetine) and NRI (viz. desipramine) treatment (both 10 mg/kg; 20 mg/kg x 21 days). We also studied behavioural responses to the 5-HT(2A/C) agonist, meta-chlorophenylpiperazine (mCPP) and the D2 agonist, quinpirole (2 mg/kg and 5 mg/kg respectively x 4 days). Deer mice showed a distinct separation into high and low stereotypic behaviour populations, with high and low dose fluoxetine, but not desipramine, significantly reducing stereotypic behaviour in both populations. A significant attenuation of stereotypy was also observed in both groups following quinpirole or mCPP challenge. In its response to drug treatment, spontaneous stereotypic behaviour in deer mice demonstrates predictive validity for OCD. States of spontaneous stereotypy are attenuated by 5-HT(2A/C) and dopamine D2 receptor agonists.


Asunto(s)
Conducta Animal/efectos de los fármacos , Desipramina/uso terapéutico , Modelos Animales de Enfermedad , Agonistas de Dopamina/uso terapéutico , Fluoxetina/uso terapéutico , Trastorno Obsesivo Compulsivo/tratamiento farmacológico , Quinpirol/uso terapéutico , Receptores de Dopamina D2/agonistas , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Agonistas del Receptor de Serotonina 5-HT2 , Conducta Estereotipada/efectos de los fármacos , Animales , Antidepresivos Tricíclicos/farmacología , Antidepresivos Tricíclicos/uso terapéutico , Conducta Animal/fisiología , Desipramina/farmacología , Agonistas de Dopamina/farmacología , Evaluación Preclínica de Medicamentos , Femenino , Fluoxetina/farmacología , Humanos , Masculino , Trastorno Obsesivo Compulsivo/psicología , Peromyscus , Piperazinas/farmacología , Quinpirol/farmacología , Agonistas de Receptores de Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Especificidad de la Especie , Conducta Estereotipada/fisiología
7.
Neuropharmacology ; 51(7-8): 1172-80, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17045620

RESUMEN

The efficacy of antidepressant drugs with serotonergic, noradrenergic, or dual reuptake inhibition was evaluated in reversing carrageenan-induced thermal hyperalgesia and mechanical allodynia in rats. Duloxetine (1-30mg/kg, i.p.), a balanced serotonergic-noradrenergic reuptake inhibitor (SNRI), was equiefficacious and more potent than the SNRI venlafaxine (3-100mg/kg, i.p.) in reversing both thermal hyperalgesia and mechanical allodynia induced by carrageenan. In addition, the selective noradrenergic reuptake inhibitors (NRIs) thionisoxetine (0.03-10mg/kg, i.p.) and desipramine (1-30mg/kg, i.p.) also produced complete reversals of carrageenan-induced thermal hyperalgesia. However, only thionisoxetine exhibited a greater than 80% reversal of the carrageenan-induced mechanical allodynia. In contrast, the selective serotonergic reuptake inhibitors (SSRIs) paroxetine, sertraline, and fluoxetine (0.3-10mg/kg i.p.) had little or no effect in the carrageenan model. In order to understand whether the observed enhanced effectiveness of the dual SNRIs was due to a possible synergism between serotonergic and noradrenergic reuptake inhibition, the effects of the NRI thionisoxetine alone and in combination with an inactive dose of the SSRI fluoxetine were determined. In the presence of fluoxetine, the potency of thionisoxetine in reversing carrageenan-induced hyperalgesia and allodynia was significantly increased by approximately 100-fold and brain concentrations of thionisoxetine were increased by 1.1- to 5-fold. The present data indicate fluoxetine pharmacodynamically potentiated the analgesic effects of thionisoxetine over and above a metabolic interaction between these two drugs. The present findings thus indicate that, in the carrageenan model, dual serotonergic-noradrenergic reuptake inhibition by dual SNRIs, or SSRI-NRI combinations, produces synergistic analgesic efficacy.


Asunto(s)
Inhibidores de Captación Adrenérgica/uso terapéutico , Analgésicos no Narcóticos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Hiperalgesia/tratamiento farmacológico , Norepinefrina/fisiología , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Serotonina/fisiología , Inhibidores de Captación Adrenérgica/farmacología , Analgésicos no Narcóticos/farmacología , Animales , Antiinflamatorios no Esteroideos/farmacología , Química Encefálica/efectos de los fármacos , Carragenina/toxicidad , Ciclohexanoles/farmacología , Ciclohexanoles/uso terapéutico , Desipramina/farmacología , Desipramina/uso terapéutico , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Clorhidrato de Duloxetina , Edema/inducido químicamente , Edema/tratamiento farmacológico , Fluoxetina/análogos & derivados , Fluoxetina/análisis , Fluoxetina/farmacología , Fluoxetina/uso terapéutico , Calor/efectos adversos , Hiperalgesia/inducido químicamente , Hiperalgesia/fisiopatología , Masculino , Paroxetina/farmacología , Paroxetina/uso terapéutico , Presión/efectos adversos , Ratas , Ratas Sprague-Dawley , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Sertralina/farmacología , Sertralina/uso terapéutico , Tiofenos/farmacología , Tiofenos/uso terapéutico , Clorhidrato de Venlafaxina
8.
Neuropharmacology ; 47(8): 1189-97, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15567428

RESUMEN

A relation between magnesium (Mg) status and mood disorders has been suggested, but evidence remains inconsistent. Therefore, we examined in mice whether Mg-depletion would alter behavior evaluated in established animal models of depression and anxiety and whether these effects would be sensitive to antidepressants. Compared to control mice fed with normal diet, mice receiving a low Mg diet (10% of daily requirement) for several weeks displayed increased immobility time in the forced swim test, indicating enhanced depression-like behavior. In addition, the partial Mg-depletion increased anxiety-related behavior in the light/dark and open field test, while locomotor activity or motor coordination was not influenced. Chronic oral administration of desipramine (30 mg/kg/day), or Hypericum extract LI160 (Hyp, 380 mg/kg/day) prevented the "pro-depression-like" forced swim behavior in Mg-depleted mice. Furthermore, the increase in anxiety-related behavior of Mg-depleted mice was abolished in both the open field and light dark test by Hyp. Taken together, we report that Mg-depletion leads to enhanced depression- and anxiety-related behavior in mice, which was further validated by the reversibility of the behavioral changes by known antidepressant and anxiolytic substances. Further, the utility of Mg-depletion as a new screening model for clinically active antidepressant and anxiolytic drugs is suggested.


Asunto(s)
Ansiedad/tratamiento farmacológico , Depresión/tratamiento farmacológico , Desipramina/uso terapéutico , Hypericum , Deficiencia de Magnesio/psicología , Animales , Ansiedad/psicología , Depresión/psicología , Desipramina/farmacología , Locomoción/efectos de los fármacos , Locomoción/fisiología , Ratones , Ratones Endogámicos C57BL , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico
10.
Pain ; 82(2): 149-158, 1999 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10467920

RESUMEN

Amitriptyline, a non-selective noradrenaline (NA) and 5-hydroxytryptamine (5-HT) reuptake inhibitor, has recently been demonstrated to produce a peripheral antinociceptive action in an inflammatory (formalin test) and a neuropathic pain model (spinal nerve ligation). In the present study, we determined whether desipramine, a selective NA reuptake inhibitor, and fluoxetine, a selective 5-HT reuptake inhibitor, could produce peripheral antinociceptive actions in these same tests. Effects on paw volume also were determined. In the 2.5% formalin test, desipramine and fluoxetine 10-300 nmol produced a dose-related reduction in phase 2 (16-60 min) flinching and biting/licking behaviours when coadministered with the formalin. Phase 1 flinch behaviours (0-12 min) were significantly reduced at the highest dose. These actions are peripherally mediated, as they were not seen when desipramine or fluoxetine (100, 300 nmol) were injected into the contralateral hindpaw. The peripheral action of desipramine and fluoxetine was not altered by coadministration of caffeine 1500 nmol. In the spinal nerve ligation model, desipramine 100 nmol, but not fluoxetine 100 nmol, produced a peripheral anti-hyperalgesic action in the hindpaw corresponding to the ligated side when thresholds were determined using a thermal paw stimulator. In paw volume experiments, desipramine, at doses which are maximally effective in behavioural tests, produced only a slight increase in paw volume, but fluoxetine (10-300 nmol) produced a robust and sustained dose-related increase in paw volume. Amitriptyline also produced minimal effects on paw volume. When coinjected with formalin, no agent significantly altered the degree of paw swelling produced by formalin. The increase in paw volume produced by fluoxetine was inhibited by ketanserin (5-HT2 receptor antagonist), mepyramine (histamine H1 receptor antagonist) and phentolamine (alpha-adrenergic receptor antagonist), but not by the other selective 5-HT receptor antagonists tested or caffeine. The pronounced peripheral pain alleviating actions in the absence of marked changes in paw volume produced by desipramine and amitriptyline, but not fluoxetine, in the formalin test and the spinal nerve ligation model suggest that these agents could be developed as cream or gel formulations to recruit a peripheral antinociceptive action in inflammatory and neuropathic pain states. Such a formulation might permit the attainment of higher and more efficacious concentrations in the region of the sensory nerve terminal, with limited systemic side effects.


Asunto(s)
Inhibidores de Captación Adrenérgica/uso terapéutico , Desipramina/uso terapéutico , Fluoxetina/uso terapéutico , Neuralgia/tratamiento farmacológico , Dolor/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Amitriptilina/uso terapéutico , Animales , Cafeína/farmacología , Evaluación Preclínica de Medicamentos , Masculino , Dimensión del Dolor , Ratas , Ratas Sprague-Dawley , Antagonistas de la Serotonina/farmacología , Nervios Espinales/efectos de los fármacos
11.
Phytomedicine ; 6(5): 319-23, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11962537

RESUMEN

In Mexico, aqueous extracts from dried leaves of Mimosa puolica are employed to alleviate depression. In this study, the behavioral actions of aqueous extracts of M. pudica at various concentrations were tested. Rats having received saline (0.9%; 0.30 ml; I.P.), clomipramine, desipramine or several dosages of aqueous extracts from M. pudica (ml = 2.0 mg/kg; m2 = 4.0 mg/kg; m3 = 6.0 mg/kg; m4 = 8.0 mg/kg) during a 30-day period were submitted to the forced swimming test and to the test for differential reinforcement of low rates of response at 72 sec (DRL-72s). Any possible anxiolytic action resulting from several doses (ml = 2.0 mg/kg; m2 = 4.0 mg/kg; m3 = 6.0 mg/kg; m4 = 8.0 mg/kg) of extracts of M. pudica were compared with those caused by diazepam (1.3 mg/kg, I.P.) in the elevated plus-maze test. Results showed that clomipramine (1.25 mg/kg, I.P.), desipramine (2.14 mg/kg, I.P.) and M. pudica (6.0 mg/kg and 8.0 mg/kg, I.P.) reduced immobility in the forced swimming test and increased the rate of reinforcers received in the DRL-72s test; these data suggest that M. pudica produces antidepressant effects in the rat. Diazepam increased the open-arms exploration time in the elevated plus-maze test, but M. pudica did not show any comparable action at any tested dose. M. pudica therefore produced an antide-pressant-like profile similar to two tricyclic antidepressants.


Asunto(s)
Antidepresivos/uso terapéutico , Depresión/tratamiento farmacológico , Fabaceae/química , Fitoterapia , Plantas Medicinales/química , Animales , Antidepresivos/aislamiento & purificación , Conducta Animal/efectos de los fármacos , Clomipramina/uso terapéutico , Desipramina/uso terapéutico , Masculino , Medicina Tradicional , México , Extractos Vegetales/uso terapéutico , Pruebas Psicológicas , Ratas , Ratas Wistar , Estrés Fisiológico/tratamiento farmacológico , Natación/psicología
12.
Pharmacol Biochem Behav ; 59(1): 171-7, 1998 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9443552

RESUMEN

Previously it has been reported that forced swim test (FST) exposure activates the HPA-axis and produces alterations in both cellular and noncellular immunity in rats. Furthermore, there is evidence to suggest that pretreatment with antidepressants has a protective effect against FST-induced immune changes. The purpose of the present study was to examine the effect of subacute treatment with the tricyclic antidepressant desipramine (DMI, 5 and 10 mg/kg; I.P.) on immobility in the FST, and on FST-induced changes in endocrine and immune parameters in the rat. DMI treatment at a dose of 10 mg/kg produced a significant reduction in immobility time in the FST, while the 5 mg/kg dose was ineffective. FST exposure produced a significant increase in serum corticosterone and a decrease in adrenal ascorbic acid concentrations, neither of which were significantly attenuated by DMI pretreatment. There was a slight but nonsignificant suppression of PHA-induced lymphocyte proliferation 15 min post-FST exposure. However, DMI treatment produced a significant increase in lymphocyte proliferation at this time point. FST exposure caused a reduction in the percentage of lymphocytes and an increase in the percentage of neutrophils in the peripheral blood; DMI treatment failed to significantly alter these stress-induced changes. There was a profound reduction in relative spleen weight observed in DMI-treated animals 120 min post-FST exposure and this was accompanied by an increase in circulating RBC concentrations. In conclusion, although the FST-induced behavioral changes were normalized by DMI treatment the peripheral aberrations induced by FST exposure (with the exception of lymphocyte proliferation) were not. In addition, DMI pretreatment induced stress-like changes in corticosterone, adrenal ascorbic acid and leucocyte subpopulations in the control animals.


Asunto(s)
Antidepresivos Tricíclicos/uso terapéutico , Depresión/tratamiento farmacológico , Desipramina/uso terapéutico , Sistema Endocrino/efectos de los fármacos , Sistema Inmunológico/efectos de los fármacos , Glándulas Suprarrenales/metabolismo , Animales , Ácido Ascórbico/metabolismo , Corticosterona/sangre , Depresión/inmunología , Depresión/fisiopatología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Leucocitos/efectos de los fármacos , Masculino , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Natación
13.
J Orofac Pain ; 8(4): 391-6, 1994.
Artículo en Inglés | MEDLINE | ID: mdl-7670427

RESUMEN

Traumatic injury to the peripheral nerves often results in persistent discomfort. Substance P has been implicated as a mediator of pain, and depletion of this neurotransmitter has been shown to reduce pain. Subjects suffering from traumatic dysesthesia of the trigeminal nerve were treated with capsaicin, a substance P depleter with significant long-term effects. This form of therapy may be used individually or in combination with other pharmacologic interventions in the treatment of traumatic trigeminal dysesthesia.


Asunto(s)
Antidepresivos Tricíclicos/uso terapéutico , Capsaicina/uso terapéutico , Dolor Facial/tratamiento farmacológico , Irritantes/uso terapéutico , Complicaciones Posoperatorias/tratamiento farmacológico , Traumatismos del Nervio Trigémino , Neuralgia del Trigémino/tratamiento farmacológico , Administración Tópica , Anciano , Capsaicina/administración & dosificación , Desipramina/uso terapéutico , Quimioterapia Combinada , Dolor Facial/etiología , Femenino , Humanos , Irritantes/administración & dosificación , Masculino , Mandíbula/cirugía , Fracturas Mandibulares/complicaciones , Nortriptilina/uso terapéutico , Parestesia/tratamiento farmacológico , Parestesia/etiología , Ritidoplastia/efectos adversos , Neuralgia del Trigémino/etiología
14.
J Nerv Ment Dis ; 179(12): 755-8, 1991 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-1744635

RESUMEN

Thirteen patients meeting DSM-III-R criteria for panic disorder with or without agoraphobia that started during or shortly after cocaine exposure were treated in the UCLA Anxiety Disorders Program (Los Angeles, CA). Low starting doses (ranging from 2.5 to 10 mg/day) of desipramine were used. Doses were then slowly increased to an average daily dose of 25 mg. Eleven patients who were able to tolerate an initial increase in panic anxiety responded to this treatment strategy with almost full resolution of panic attacks. The authors discuss the possible value and mechanisms of low dose treatment of cocaine-related panic attacks.


Asunto(s)
Cocaína , Desipramina/administración & dosificación , Trastorno de Pánico/tratamiento farmacológico , Trastornos Relacionados con Sustancias/complicaciones , Adulto , Cocaína/efectos adversos , Desipramina/uso terapéutico , Esquema de Medicación , Evaluación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastorno de Pánico/etiología , Trastorno de Pánico/psicología , Escalas de Valoración Psiquiátrica , Terapia por Relajación
16.
Fed Proc ; 44(10): 2640-4, 1985 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-3924665

RESUMEN

Anticonvulsant drugs were evaluated in members of two colonies of genetically epilepsy-prone rats (GEPR). Virtually all of the animals in the first colony experience a wild running fit that terminates in a generalized clonic convulsion when they are stimulated by sound. According to our convulsion intensity scoring system, these animals have an audiogenic response score (ARS) of 3 and the colony is designated the GEPR-3 colony. In the second colony, more than 95% of the animals experience a wild running phase terminating in a tonic extensor convulsion when they are stimulated by sound. That is, they have an ARS of 9 and the colony is designated the GEPR-9 colony. All of the established antiepileptic drugs that were tested produced anticonvulsant effects in the GEPR. Three tricyclic antidepressant agents acted as anticonvulsants in doses substantially lower than the toxic doses that produced spontaneous convulsions. Two of the established anticonvulsants, phenobarbital and ethosuximide, produced anticonvulsant effects in very similar doses in members of GEPR-3 and GEPR-9 colonies. Valproic acid produced an anticonvulsant effect in GEPR-3 in significantly lower doses than in GEPR-9. Carbamazepine, phenytoin, imipramine, amitriptyline, and desipramine produced anticonvulsant effects in essentially equimolar doses and in each case the protective dose was significantly lower in GEPR-9 than in GEPR-3 colonies. GEPR did not experience the convulsive effects of imipramine, amitriptyline, and desipramine at lower doses than did control animals. Thus, these epilepsy-prone animals are no more likely to experience convulsions in response to overdose of one of these three drugs than are nonepileptic subjects.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Modelos Animales de Enfermedad , Epilepsia/tratamiento farmacológico , Estimulación Acústica , Amitriptilina/uso terapéutico , Animales , Carbamazepina/uso terapéutico , Desipramina/uso terapéutico , Etosuximida/uso terapéutico , Imipramina/uso terapéutico , Fenobarbital/uso terapéutico , Fenitoína/uso terapéutico , Ratas , Ratas Endogámicas , Convulsiones/tratamiento farmacológico , Ácido Valproico/uso terapéutico
17.
Psychiatry Res ; 13(4): 345-52, 1984 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-6596590

RESUMEN

Higher electromyographic (EMG) activity levels of corrugator and zygomatic face muscles have been reported to be pretreatment predictors of better clinical outcome in depressed patients. We tested this possibility in 29 drug-free, rigorously diagnosed subjects by measuring low-level EMG activity of corrugator and zygomatic muscles during resting and three imagery states (happy, typical day, sad). All patients had major depressive disorder, endogenous subtype. Good responders had significantly higher pretreatment EMG zygomatic values and different EMG profiles. Our findings replicate and expand prior reports.


Asunto(s)
Antidepresivos/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Electromiografía/métodos , Músculos Faciales/efectos de los fármacos , Contracción Muscular/efectos de los fármacos , Amitriptilina/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/psicología , Desipramina/uso terapéutico , Expresión Facial , Femenino , Humanos , Imipramina/uso terapéutico , Maprotilina/uso terapéutico , Persona de Mediana Edad , Pronóstico , Escalas de Valoración Psiquiátrica
18.
Acta Psychiatr Scand ; 66(1): 66-82, 1982 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-6181652

RESUMEN

In a comparative evaluation of zimelidine, a potent serotonin (5-HT) uptake inhibitor, and desipramine, a potent noradrenaline (NA) uptake inhibitor, 65 hospitalized patients with endogenous depression were evaluated for the following biochemical variables: 5-HT uptake in platelets, 5-HT concentration in whole blood, inhibition of the 5-HT and NA accumulation in rat hypothalamic synaptosomes incubated in the patients' plasma, the excretion of 4-hydroxy-3-methoxyphenyl glycol (HMPG) in urine and the pretreatment levels of the amine metabolites 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) and HMPG in cerebrospinal fluid (CSF). results of the biochemical studies confirmed that zimelidine and desipramine have different profiles with respect to monoamine uptake. Thus zimelidine caused more marked inhibition of 5-HT uptake than desipramine, especially in rat brain synaptosomes incubated in the patient's plasma. Desipramine plasma was much more effective than zimelidine plasma in inhibiting NA uptake in the same preparation. The urinary excretion of HMPG decreased significantly during desipramine treatment but remained unchanged during zimelidine treatment. The combined clinical and biochemical results indicated that patients with low pretreatment levels of 5-HIAA and HVA in CSF responded significantly better to zimelidine than patients with high levels of 5-HIAA and HVA. On the other hand, patients with high levels of 5-HIAA and HVA. On the other hand, patients with high levels of HMPG in CSF tended to respond better to desipramine than those with low levels of this NA metabolite.


Asunto(s)
Antidepresivos/uso terapéutico , Bromofeniramina/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Desipramina/uso terapéutico , Norepinefrina/metabolismo , Piridinas/uso terapéutico , Serotonina/metabolismo , Adulto , Anciano , Animales , Plaquetas/metabolismo , Bromofeniramina/análogos & derivados , Trastorno Depresivo/metabolismo , Método Doble Ciego , Femenino , Ácido Homovanílico/líquido cefalorraquídeo , Humanos , Ácido Hidroxiindolacético/líquido cefalorraquídeo , Hipotálamo/metabolismo , Masculino , Metoxihidroxifenilglicol/líquido cefalorraquídeo , Persona de Mediana Edad , Ratas , Sinaptosomas/metabolismo , Zimeldina
20.
J Urol ; 116(5): 638-43, 1976 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-978818

RESUMEN

Recently, a study was made of 8 boys with complications after corrective surgical procedures for dysfunction of the voiding mechanism. One of these patients already had been subjected to irreversible diversion before the basic disorder was recognized but the majority was treated with suggestion (often with hypnosis) as well as with drugs affecting the smooth muscle (1 adolescent was too hostile to accept treatment). Because the bladder was dysfunctional, the operations either failed or sequelae persisted until measures such as suggestion, hypnotherapy and retraining reversed the incoordination of micturition. Operation or reoperation in 5 children might not have been necessary if bladder coordination had been established earlier. The case of boys with poor urinary control but free of neurologic stigmas are suspect. If they require an operation for repair of congenital urinary defects such as reflux, equal attention must be paid to psychologic and habit patterns causing bladder dysfunction. Otherwise, the operation is done essentially into a neurogenic bladder. It is concluded that psychologically conditioned incoordination of voiding may alone produce mid and upper tract damage. The cases of boys with problems of urinary control not explained by neurologic or anatomic defects should be suspected and corrective surgical procedures may fail if bladder dysfunction is not corrected by retraining, suggestion and even hypnotherapy.


Asunto(s)
Complicaciones Posoperatorias/terapia , Uréter/cirugía , Vejiga Urinaria/cirugía , Trastornos Urinarios/cirugía , Niño , Preescolar , Desipramina/uso terapéutico , Impactación Fecal/fisiopatología , Humanos , Hipnosis , Masculino , Radiografía , Control de Esfínteres , Vejiga Urinaria/anomalías , Vejiga Urinaria/fisiopatología , Obstrucción del Cuello de la Vejiga Urinaria/cirugía , Infecciones Urinarias/cirugía , Trastornos Urinarios/fisiopatología , Trastornos Urinarios/terapia , Reflujo Vesicoureteral/diagnóstico por imagen
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA